Identification of chemoresistance targets in doxorubicin-resistant lung adenocarcinoma cells using LC-MS/MS-based...

Area of Science:

• Proteomics
• Cancer Biology
• Molecular Oncology

Background:

• Acquired chemoresistance is a major clinical hurdle, leading to treatment failure in many cancers.
• Identifying novel therapeutic targets is essential for overcoming drug resistance and improving patient outcomes.

Purpose of the Study:

• To identify potential therapeutic targets and signaling pathways associated with acquired chemoresistance.
• To investigate the molecular mechanisms underlying doxorubicin (DOX) resistance in lung adenocarcinoma cells.

Main Methods:

• Label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantitative proteomics was used.
• Differential protein expression analysis was performed on A549DR cells (doxorubicin-resistant) versus A549 cells (parental).
• Bioinformatic analyses including KEGG pathway, Gene Ontology (GO), and STRING for protein-protein interaction (PPI) network analysis were conducted.

Main Results:

• Proteomics identified 146 upregulated and 129 downregulated proteins in A549DR cells.
• Upregulated pathways included metabolic pathways, cellular senescence, cell cycle, and p53 signaling.
• Downregulated pathways involved spliceosome, nucleotide metabolism, DNA replication, nucleotide excision repair, and nuclear-cytoplasmic transport.
• Key upregulated proteins with PPIs included CDK1, AKT2, SRC, STAT1, HDAC1, FDXR, FDX1, NPC1, ALDH2, GPx1, CDK4, and B2M.

Conclusions:

• The study identified several proteins and pathways implicated in acquired doxorubicin resistance.
• These proteins, including CDK1, AKT2, and SRC, represent potential therapeutic targets for overcoming chemoresistance.
• Further research into these targets could lead to novel strategies for managing drug-resistant lung adenocarcinoma.